Clinical trial NCT05637788: Artificial Intelligence and Hepatocellular Carcinoma
Official title: Artificial Intelligence and Hepatocellular Carcinoma
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: HCC
Keywords: HCC
hepatocellular carcinoma
hepatectomy
liver primary tumor
recurrence
artificial intelligence
machine learning
prognostic prediction
microvascular invasion
Lead sponsor: Humanitas Clinical and Research Center
Sponsor class: OTHER
Collaborators: name: San Gerardo Hospital
name: Ospedale "Carlo Poma" - Mantova
name: Ospedale Centrale di Bolzano
name: University of Pavia
name: Morgagni Pierantoni Hospital
name: Regina Elena Cancer Institute
name: Universita di Verona
name: University of Milano Bicocca
name: Treviso Regional Hospital
name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
name: Miulli General Hospital
name: Federico II University
name: Research Institute Against Digestive Cancer IRCAD
First posted: 2022-12-05
Enrollment: 535
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients affected by hepatocellular carcinoma (first diagnosis) treated by liver resection.

Brief summary: To identify new relevant biomarkers for HCC patients and their risk of recurrence. Radiomics data and computer-vision data will be explored for their ability to predict the presence of particular pathological signs of aggressiveness (microvascular invasion and satellitosis), and the prognosis after surgery.

Detailed description: Hepatocellular carcinoma (HCC) is 1 of the 5 most common malignancies worldwide and the third most common cause of cancer related mortality of 500,000 deaths globally every year.

Although more common in East Asia, the incidence of HCC is increasing in the Western world. Hepatic resection is the first-line therapeutic option, and it is accepted as a safe treatment with a proven impact on prognosis, with a low operative mortality as the result of advances in surgical techniques and perioperative management. Nevertheless, surgical resection is applicable in only about 20% to 30% of patients with HCC, since most have poor hepatic reserve function caused by underlying chronic liver disease and multi focal hepatic distributions of HCC. Although hepatic resection is one of the curative treatments for hepatocellular carcinoma, the recurrence rate of HCC even after curative resection is quite high, estimated to be approximately 50 % during the first 3 years and more than 70 % during the first 5 years after curative resection, and so the postoperative long term results remain unsatisfactory. In this scenario the role of liver transplantation has been, in the last years, predominant, due to the ability of transplant to reduce disease recurrence, because of the treatment of liver cirrhosis associate to HCC which represent the most important driver to recurrence. Otherwise, the scarcity of organ source has been a boost to the spread of liver resection, not only confined in the boundary taken into account in the BCLC algorithm (guidelines endorsed by EASL and AASLD), but even in patients considered not suitable for curative treatment as well as liver resection. Although surgical treatment has been adopted in the last years in more patients outside the Guidelines with satisfactory results in terms of mortality, morbidity and Short term oncological outcomes, the limits of this approach remain the long term disease free survival.

Risk factor for recurrence has been yet identified in the last years as hcc dimension, grading, microvascular invasion and satellitosis. The evidence that these two prognostic factors could negatively impact on the long term prognosis enhancing the risk of recurrence, has led many Author to propose anatomical resection (segmental resection) as the ideal surgical treatment to reduce these risks in HCC patients. Otherwise, literature results are in conflict regarding the real benefit of this approach. In fact in many patients with HCC and underlying cirrhosis the anatomical approach is not feasible due to the risk of postoperative liver failure. So a parenchyma-sparing technique has been developed and compared to anatomical resection in terms of oncological outcomes. At the present, all these risk factors are not predictable, and the staging systems are based only on crude radiological features as the number and the size of the nodules. In the recent years, several authors proposed new approaches to increase our ability to extract data from the radiological imaging: by the analysis of the measurements and numbers obtained during the radiological acquisition (by CT or MRI scans), thousands of other information are obtainable, overcoming the ability of human eyes. Those techniques go under the names of "Radiomics", which is a very promising branch when merged with the novel machine learning algorithms (e.g. Deep Learning, Neural Networks, etc). Moreover, nowadays, novel data can be obtained also by simple intraoperative photo obtained during the surgical procedure, for example of the liver cut surface: by the "computer-vision analysis", another powerful machine-learning algorithm, other data can be produced to predict short and long term outcomes. Those potentialities rely on the modern field of "artificial intelligence", where a machine is trained to recognize different recurrent patterns to create prediction models with a very powerful accuracy. On these data is based the proposal to create the present multicentric study with the aim to develop a prediction model for post-operative complications and HCC recurrence, based on the analysis of CT-radiomics features, liver cut surface photos and machine learning analysis.

Eligibility criteria: Inclusion Criteria:

* Age \>= 18 years old.
* Hepatocarcinoma diagnosis confirmed at histological specimen
* Being at the first HCC diagnosis or with a recurrence/persistence disease evaluated and treated for the first time with surgery at the participating center.
* Available contrast-enhanced CT Scan obtained no more than 1 month prior to surgery.

Exclusion Criteria:

* Surgery as a downstaging therapy for transplant
* Patients treated with surgery in case of not-curative intent (palliation, best supportive care, etc).
* Histopathological specimen of combined liver primary neoplasms (e.g. 'epatocolangiocarcinoma').

Primary outcomes:
measure: Evaluate the association between different radiomics and computer-vision features, and the survival after surgery
timeFrame: 1 Year and 4 Months
Secondary outcomes:
measure: Evaluate the association between different radiomics and computer-vision features, and the short-terms results after surgery
timeFrame: 1 Year and 4 Months
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: IRCCS Istituto Clinico Humanitas
state: Lombardy
Study officials:
References: